Jiangsu Hengrui Medicine
600276.SS
#504
Rank
NZ$71.42 B
Marketcap
$11.20
Share price
-1.09%
Change (1 day)
13.70%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): NZ$1.34 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are NZ$3.63 Billion. In 2023 the company made an earning of NZ$1.16 Billion, an increase over its 2022 earnings that were of NZ$1.04 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) NZ$1.34 B15.35%
2023 NZ$1.16 B11.4%
2022 NZ$1.04 B-13.65%
2021 NZ$1.21 B-34.21%
2020 NZ$1.84 B15.95%
2019 NZ$1.59 B33.03%
2018 NZ$1.19 B20.89%
2017 NZ$0.99 B23.89%
2016 NZ$0.79 B11.21%
2015 NZ$0.71 B39.5%
2014 NZ$0.51 B20.61%
2013 NZ$0.42 B11.46%
2012 NZ$0.38 B29.7%
2011 NZ$0.29 B31.16%
2010 NZ$0.22 B27.92%
2009 NZ$0.17 B5.8%
2008 NZ$0.16 B79.95%
2007 NZ$92.58 M32.89%
2006 NZ$69.67 M38.19%
2005 NZ$50.41 M21.56%
2004 NZ$41.47 M13.95%
2003 NZ$36.39 M38.06%
2002 NZ$26.36 M